Barclays
STOK icon

Barclays’s Stoke Therapeutics STOK Stock Holding History

Barclays’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.33M Buy
51,185
+36,579
+250% +$1.1M ﹤0.01% 2857
2026
Q2 		$478K Buy
14,606
+4,487
+44% +$144K ﹤0.01% 3256
2026
Q1 		$329K Sell
10,119
-140,826
-93% -$4.62M ﹤0.01% 3427
2025
Q4 		$4.79M Buy
150,945
+43,222
+40% +$1.3M ﹤0.01% 2250
2025
Q3 		$2.53M Sell
107,723
-32,177
-23% -$551K ﹤0.01% 2708
2025
Q2 		$1.59M Buy
139,900
+71,539
+105% +$679K ﹤0.01% 3031
2025
Q1 		$455K Sell
68,361
-11,751
-15% -$110K ﹤0.01% 3586
2024
Q4 		$884K Buy
80,112
+372
+0.5% +$4.57K ﹤0.01% 3456
2024
Q3 		$980K Buy
79,740
+47,239
+145% +$669K ﹤0.01% 3372
2024
Q2 		$439K Buy
32,501
+11,877
+58% +$160K ﹤0.01% 3116
2024
Q1 		$278K Sell
20,624
-18,647
-47% -$113K ﹤0.01% 3934
2023
Q4 		$207K Buy
39,271
+30,831
+365% +$132K ﹤0.01% 4403
2023
Q3 		$33.3K Sell
8,440
-6,389
-43% -$42K ﹤0.01% 4026
2023
Q2 		$158K Sell
14,829
-8,031
-35% -$85.4K ﹤0.01% 3365
2023
Q1 		$190K Buy
22,860
+4,417
+24% +$39.8K ﹤0.01% 3817
2022
Q4 		$170K Buy
18,443
+7,880
+75% +$81.9K ﹤0.01% 3936
2022
Q3 		$135K Buy
10,563
+642
+6% +$10.2K ﹤0.01% 3397
2022
Q2 		$131K Buy
9,921
+5,236
+112% +$79.5K ﹤0.01% 3658
2022
Q1 		$98K Sell
4,685
-18,484
-80% -$370K ﹤0.01% 3790
2021
Q4 		$556K Buy
23,169
+14,000
+153% +$334K ﹤0.01% 3158
2021
Q3 		$233K Sell
9,169
-1,844
-17% -$51.4K ﹤0.01% 3540
2021
Q2 		$370K Sell
11,013
-6,634
-38% -$235K ﹤0.01% 3243
2021
Q1 		$686K Buy
17,647
+12,514
+244% +$712K ﹤0.01% 3001
2020
Q4 		$318K Sell
5,133
-1,682
-25% -$77.1K ﹤0.01% 3520
2020
Q3 		$229K Sell
6,815
-3,166
-32% -$90.4K ﹤0.01% 3759
2020
Q2 		$239K Buy
9,981
+3,783
+61% +$89.8K ﹤0.01% 3929
2020
Q1 		$142K Sell
6,198
-3,638
-37% -$89.9K ﹤0.01% 4539
2019
Q4 		$278K Buy
9,836
+3,835
+64% +$96.5K ﹤0.01% 4778
2019
Q3 		$129K Buy
6,001
+5,087
+557% +$142K ﹤0.01% 5295
2019
Q2 		$27K Buy
+914
New +$24.5K ﹤0.01% 6337

Other funds holding STOK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
SYM Financial Corp
SYM Financial Corp Winona Lake, Indiana $1.31B AUM 18.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return

Barclays's STOK Position: Q3 2026 in Review

Barclays increased its Stoke Therapeutics (STOK) stake by 250% in Q3 2026, buying an estimated $1.1M and bringing the position to 51,185 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2857.

Barclays first reported a position in STOK in Q2 2019 and has held it in 30 quarters since. The position peaked at $4.79M in Q4 2025. 57 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Barclays held 51,185 shares of Stoke Therapeutics worth $1.33M as of Q3 2026.
  • Barclays bought 36,579 Stoke Therapeutics shares in Q3 2026, an estimated $1.1M.
  • Stoke Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2857 holding.
  • Barclays first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 30 quarters since.
  • Barclays's Stoke Therapeutics position peaked at $4.79M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.